Improving Treatment Approaches for Rectal Cancer
Mené sur 12 patients atteints d'un cancer du rectum de stade localement avancé et présentant une déficience du système de réparation MMR, cet essai prospectif de phase II évalue l'efficacité, du point de vue du maintien de la réponse complète pendant les 12 mois qui suivent la fin du traitement, et la toxicité du dostarlimab, un anticorps anti-PD-1
The cure rate for nonmetastatic rectal cancer has been improving for decades. Treatment for stage II and III rectal adenocarcinomas now routinely includes surgery, radiation therapy, and chemotherapy. The results of recent phase 3 trials have led to an increase in the intensity of treatment to include multiagent chemotherapy in addition to radiation therapy before proctectomy is performed; such treatment has resulted in a 3-year disease-free survival rate as high as 77%.1,2 Unfortunately, this treatment approach is grueling and can cause substantial long-term sequelae, including neuropathy, infertility, and bowel and sexual dysfunction. However, this more aggressive preoperative treatment also opens . . .
New England Journal of Medicine , éditorial, 2021